Decline is not inevitable.
A daily, evidence-graded view of everything moving in kidney research : the drugs that slow decline, the science of regeneration, and the mind-body work.
Two small studies offer hints about kidney safety for certain cancer treatments and lifestyle changes
Today’s research updates come from two observational studies with limited strength. One looks at how a kidney-cleared cancer drug affected men who already had kidney disease, but the small size and lack of comparison group mean results are uncertain. The other study tracked blood pressure changes after a lifestyle program but did not assess kidney-specific measures like eGFR or proteinuria, so it doesn’t provide direct insight for kidney health.
Impact of a Residential Yoga and Naturopathy-based Lifestyle Modification on Cardio-Metabolic Risk Factors in Patients with Hypertension: A Retrospective Study.
Researchers looked back at records of people with high blood pressure who stayed at a live-in center doing yoga and naturopathy, and compared heart and metabolic numbers before and after. Looking back at charts with no comparison group shows a link, not proof of cause: the people who choose a residential program differ from those who do not. The abstract gives no number of patients, no length of stay, and no size of effect. It also measured blood pressure and metabolic risk, not kidney filtering rate (eGFR) or protein in the urine, so it says nothing directly about kidneys.
¹⁷⁷Lu-PSMA Radioligand Therapy in Metastatic Castration-resistant Prostate Cancer With Complex Renal Conditions: A Case Series.
Doctors treated men with advanced prostate cancer using a radioactive drug, Lu-177 PSMA, that the kidneys clear from the body. These men also had kidney problems, so they are usually left out of trials and there is little safety information for them. This report describes what happened to the small group the team treated, including how their kidneys held up. It is a case series with no comparison group and no reported patient count in the abstract, so it shows a link at best, not proof of cause.
Paediatric proteomic signatures of cardiometabolic disease-associated traits predict adult disease outcomes.
Researchers measured blood proteins in 273 Hispanic and Latino children and teens, average age about 13, and matched them to 25 early signs of trouble in the liver, body fat, blood vessels and blood sugar. Those signs belong to a cluster doctors call cardiovascular-kidney-metabolic disease, which can later include kidney damage. The study shows a link between childhood protein patterns and adult disease risk, not proof that the proteins cause it. It did not measure kidney filtering rate (eGFR) or protein in the urine, so the kidney part of that link is still indirect.